NCT05541627View on ClinicalTrials.gov

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

April 4, 2024

Study Completion Date

April 30, 2028

Conditions
Huntington Disease
Interventions
GENETIC

AB-1001 Gene Therapy

One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene

Trial Locations (1)

75013

Institut du Cerveau (ICM), Hôpital La Pitié Salpêtrière APHP, Paris

All Listed Sponsors
lead

Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)

INDUSTRY

NCT05541627 - A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease | Biotech Hunter | Biotech Hunter